26129-32-8

Basic information

• Product Name: Clofop
• Synonyms: Brn 1996227;Clofop [iso];Hoe 19453;Lf 479;Propanoic acid, 2-(4-(4-chlorophenoxy)phenoxy)-;2-[4-(4-chlorophenoxy)phenoxy]-;Clofop;LABOTEST-BB LT00239222
• CAS NO: 26129-32-8
• Molecular Formula: C₁₅H₁₃ClO₄
• Molecular Weight: 292.72
• EINECS: 255-626-9
• Product Categories: API intermediates
• Mol File: 26129-32-8.mol

Chemical Properties

• Boiling Point: 405.77°C (rough estimate)
• Flash Point: 215 °C
• Appearance: /
• Density: 1.2455 (rough estimate)
• Vapor Pressure: 3.17E-08mmHg at 25°C
• Refractive Index: 1.4429 (estimate)
• PKA: 3.22±0.10(Predicted)
• CAS DataBase Reference: Clofop(CAS DataBase Reference)
• NIST Chemistry Reference: Clofop(26129-32-8)
• EPA Substance Registry System: Clofop(26129-32-8)

Safety Data

• Hazardous Substances Data: 26129-32-8(Hazardous Substances Data)

Usage

Uses

Used in Agriculture:
Clofop is used as a herbicide for controlling broadleaf weeds in various crops.
It is used to inhibit the action of acetolactate synthase, disrupting the biosynthesis of branched-chain amino acids and leading to the suppression of protein synthesis in target weeds.
Clofop's selective action makes it suitable for use in crops such as soybeans, corn, and wheat, without causing significant harm to the crops themselves.
Used in Weed Management:
Clofop is used to manage and control the growth of broadleaf weeds in agricultural fields.
Its application helps in reducing the competition between weeds and crops for nutrients, water, and sunlight, ensuring better crop growth and yield.
Clofop's effectiveness in controlling broadleaf weeds contributes to improved crop productivity and reduced labor and time required for manual weed control.
However, it is important to note that the use of Clofop has raised concerns about its potential environmental and health impacts, as well as the development of herbicide-resistant weeds. As a result, its usage and application are closely regulated in many countries to minimize these risks.

InChI:InChI=1/C15H13ClO4/c1-10(15(17)18)19-12-6-8-14(9-7-12)20-13-4-2-11(16)3-5-13/h2-10H,1H3,(H,17,18)

Upstream product

• 21567-18-0 4-(4-chlorophenoxy)phenol 
• 535-11-5 Ethyl 2-bromopropionate 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 40843-46-7 4-(4-chlorophenoxy)anisole 
• 106-48-9 4-chloro-phenol 
• 51337-67-8 D-(+)-2-[4-(4-chlorophenoxy)-phenoxy]propionic acid ethyl ester 
• 49562-28-9 fenofibrate 

Downstream Products

• 51337-85-0 N-Butyl-2-[4-(4-chloro-phenoxy)-phenoxy]-N-methyl-propionamide 
• 51337-75-8 2-[4-(4-Chloro-phenoxy)-phenoxy]-thiopropionic acid S-propyl ester 
• 65633-47-8 2-[4'-(4-chlorophenoxy)phenoxy]-propionic acid 4-chlorobut-1-yl ester 
• 51337-90-7 2-[4-(4-Chloro-phenoxy)-phenoxy]-N-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-propionamide 
• 64380-94-5 2-[4-(4-Chloro-phenoxy)-phenoxy]-propionic acid (2-chloro-phenoxycarbonylamino)-methyl ester 
• 64855-75-0 2-<4-(4-Chlorphenoxy)-phenoxy>-propionsaeureamid 
• 51337-89-4 2-[4-(4-Chloro-phenoxy)-phenoxy]-N-(3-trifluoromethyl-phenyl)-propionamide 
• 51337-87-2 2-[4-(4-Chloro-phenoxy)-phenoxy]-N-(4-chloro-phenyl)-propionamide 
• 66497-84-5 2-[4-(4-Chloro-phenoxy)-phenoxy]-propionic acid methoxycarbonylmethyl ester 
• 51337-81-6 2-[4-(4-Chloro-phenoxy)-phenoxy]-thiopropionic acid S-phenyl ester 
• 51337-83-8 2-[4-(4-Chloro-phenoxy)-phenoxy]-N,N-dimethyl-propionamide 
• 51337-84-9 2-[4-(4-Chloro-phenoxy)-phenoxy]-N,N-diethyl-propionamide 
• 51337-82-7 2-[4-(4-Chloro-phenoxy)-phenoxy]-thiopropionic acid S-(4-chloro-phenyl) ester 
• 51337-88-3 2-[4-(4-Chloro-phenoxy)-phenoxy]-N-(3,4-dichloro-phenyl)-propionamide 

Relevant articles and documents

Functional and Structural Insights into Human PPARα/δ/Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate

Among the agonists against three peroxisome proliferator-activated receptor (PPAR) subtypes, those against PPARα (fibrates) and PPARγ (glitazones) are currently used to treat dyslipidemia and type 2 diabetes, respectively, whereas PPARδ agonists are expected to be the next-generation metabolic disease drug. In addition, some dual/pan PPAR agonists are currently being investigated via clinical trials as one of the first curative drugs against nonalcoholic fatty liver disease (NAFLD). Because PPARα/δ/γ share considerable amino acid identity and three-dimensional structures, especially in ligand-binding domains (LBDs), clinically approved fibrates, such as bezafibrate, fenofibric acid, and pemafibrate, could also act on PPARδ/γ when used as anti-NAFLD drugs. Therefore, this study examined their PPARα/δ/γ selectivity using three independent assays—a dual luciferase-based GAL4 transactivation assay for COS-7 cells, time-resolved fluorescence resonance energy transfer-based coactivator recruitment assay, and circular dichroism spectroscopy-based thermostability assay. Although the efficacy and efficiency highly varied between agonists, assay types, and PPAR subtypes, the three fibrates, except fenofibric acid that did not affect PPARδ-mediated transactivation and coactivator recruitment, activated all PPAR subtypes in those assays. Furthermore, we aimed to obtain cocrystal structures of PPARδ/γ-LBD and the three fibrates via X-ray diffraction and versatile crystallization methods, which we recently used to obtain 34 structures of PPARα-LBD cocrystallized with 17 ligands, including the fibrates. We herein reveal five novel high-resolution structures of PPARδ/γ–bezafibrate, PPARγ–fenofibric acid, and PPARδ/γ–pemafibrate, thereby providing the molecular basis for their application beyond dyslipidemia treatment.

Double emulsion techniques for making novel compositions containing gluten and polysaccharides that contain uronic acid residues useful for encapsulating fats, oils and solids

Method of making compositions comprising gluten and polysaccharides that contain uronic acid residues encapsulating fats, oils and solids comprising double emulsion techniques.

Compositions containing gluten and polysaccharides that contain uronic acid residues useful for encapsulating fats, oils and solids

The present invention relates to compositions useful for encapsulating fats, oils or solids, comprising gluten and polysaccharides that contains uronic acid residues.

Pesticidal concentrate compositions

A pesticidal concentrate comprising a pesticidal component suspended in an oily component, the composition comprising 1-55% by weight of pesticide, 20-90% by weight of the oily component and 1-45% by weight of a surfactant component, and optionally water and optionally filler, the surfactant component comprising one or more stabilizing constituents comprising a C5-30 hydrocarbylene chain carrying a group capable of forming hydrogen bonds with water, and optionally one or more other constituents selected from the group consisting of non-ionic and ionic surfactants, the stabilizing constituent being present in an amount of at least 4% by weight, calculated on the total amount of surfactant component in the composition. Examples of stabilizing constituents are fatty alcohols and amino group-containing surfactants, especially ampholytes. Pesticidal concentrate compositions comprising 1-55% by weight of finely ground dithiocarbamate or glyphosate suspended in 10-90% by weight of an oily component and comprising 1-50% by weight of a surfactant component, calculated on the total composition, may be prepared. The pesticidal concentrate compositions are used in the preparation of ready-to-use-spray liquid, normally comprising 0.1-10% of concentrate and 90-99.9% of water.

Herbicidal esters of D-1-(phenoxy-4-phenoxy)propionic acid

Optically active enantiomers of the formula I STR1 where R is a group of the formulae STR2 R1 and R2, among others, are halogen or CF3 and Z is a carboxyl, carboxylate, carboxylic acid ester, thioester, carbonamide, carboxylic acid anilide, carbohydrazide or thioamide group, are interesting herbicides the effect of which is considerably superior to that of the optically inactive racemates.

Process for the preparation of (phenoxy- or benzyl-)-phenoxypropionic acids and their alkali metal salts

Process for the preparation of (phenoxy- or benzyl-)-phenoxypropionic acids and the alkali metal salts thereof by adding a double molar amount of an aqueous alkali hydroxide to a boiling mixture of a (benzyl- or phenoxy-)-phenol and 2-chloropropionic acid

2-[P-(p-Substituted phenoxy)phenoxy]propionyl oximes

2-[p-(p-substituted phenoxy)phenoxy] propionyl oximes, processes for their preparation, herbicidal compositions containing these oximes and methods of use of the herbicidal compositions are disclosed.

HCG 004, a new highly potent hypolipidaemic drug

In normolipidemic and hyperlipidemic animals 2 [4(4' chlorophenoxy) phenoxy] propionic acid (HCG 004) is a well tolerated and highly effective oral hypolipidemic drug. Within the hypolipidemically interesting dosage range no other pharmacological or chronic toxicological effects were found contraindicating the therapeutic use in humans.